Nuvectra Corporation announced that it has filed its regulatory submission with the U.S. Food and Drug Administration (FDA) for full-body MR-conditional approval for the Company's Algovita SCS system. This submission, pending regulatory approval from the FDA, would position the Company to achieve MR-conditional approval at or around year end 2019 following a 180-day review process.